Zura Bio Limited (ZURA)
US — Healthcare Sector
Automate Your Wheel Strategy on ZURA
With Tiblio's Option Bot, you can configure your own wheel strategy including ZURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZURA
- Rev/Share 0.0
- Book/Share 1.4753
- PB 2.4377
- Debt/Equity 0.0
- CurrentRatio 8.3967
- ROIC -0.5374
- MktCap 211633779.0
- FreeCF/Share -0.4634
- PFCF -4.8438
- PE -4.5293
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4806
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZURA | H.C. Wainwright | -- | Neutral | -- | $5 | Sept. 5, 2024 |
News
About Zura Bio Limited (ZURA)
- IPO Date 2023-03-21
- Website https://zurabio.com
- Industry Biotechnology
- CEO Robert Lisicki
- Employees 30
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.